SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment

Dalin Zhang, Aaron Lindstrom, Edward Kim, Chang‐Il Hwang, Madison Lee Hall, Tzu‐yin Lin, Yuanpei LiFrontiers in Oncology 2022 · DOI

TL;DR

This study identifies SEMA3C as a key player in pancreatic cancer progression, particularly in tumors with the KRAS G12D mutation. SEMA3C promotes cancer cell survival by inducing autophagy and creating an immunosuppressive tumor microenvironment, suggesting it's a promising therapeutic target.

What Problem Does This Paper Address?

Pancreatic cancer remains a formidable challenge with a dismal prognosis and limited effective treatment options. While targeting the mutated KRAS gene, a known driver in pancreatic cancer, is a major focus, identifying specific vulnerabilities and therapeutic targets remains crucial. This paper addresses the need to understand the molecular mechanisms driving pancreatic cancer progression, especially in the context of specific KRAS mutations like G12D, and to uncover novel therapeutic targets beyond direct KRAS inhibition.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized public databases like TCGA, cBioPortal, GEPIA, TIMER, and Oncomine to analyze gene expression data, correlate SEMA3C expression with KRAS mutations and patient survival, and investigate signaling pathways.
  • In Vitro Studies:
    • Cell Culture and Transfection: Various pancreatic cancer cell lines (BxPC3, PANC1, PACA2, KPC) and control cells (3T3, 293T, A549, Hela) were used. Gene knockdown (siRNA) and overexpression (plasmids, lentivirus) were performed to study SEMA3C and KRAS roles.
  • Immunoblotting: Western blots were used to detect protein levels of key molecules involved in autophagy (p62, LC3B, ULK1) and other cellular processes.
  • Growth and Colony Formation Assays: Standard assays were used to measure the impact of SEMA3C manipulation on cancer cell proliferation and colony formation.
  • Cell Cycle and Apoptosis Analysis: Flow cytometry was used to assess cell cycle distribution and apoptosis/necrosis.
  • Confocal Microscopy: Used to visualize autophagy flux using GFP/RFP-LC3B labeled cells.
  • RT-PCR: To quantify mRNA levels of target genes.
  • In Vivo Studies:
    • Xenograft Models: Subcutaneous tumor models were established in mice using KPC cells. These models were treated with a SEMA3C inhibitor or vehicle to assess its impact on tumor growth and weight.
  • Histological Analysis: H&E staining and immunohistochemistry (IHC) for Ki67, cleaved-caspase 3, and CD8a were performed on tumor tissues to evaluate proliferation, apoptosis, and immune cell infiltration.
  • Complete Blood Counts: Analyzed to assess potential toxicity of the SEMA3C inhibitor.

Datasets

The study utilized publicly available datasets for analysis:

  • TCGA (The Cancer Genome Atlas): A comprehensive resource for genomic and molecular data from various cancer types, including pancreatic cancer.
  • GEO (Gene Expression Omnibus): A public repository of high-throughput gene expression data.
  • cBioPortal: A platform for exploring, visualizing, and analyzing multidimensional cancer genomics data.
  • GEPIA (Gene Expression Profiling Interactive Analysis): A web server for analyzing RNA sequencing expression data from TCGA and GTEx.
  • TIMER (Tumor IMmune Estimation Resource): A web server for analyzing the tumor microenvironment, including immune cell infiltration.
  • KM plot (Kaplan-Meier plotter): A tool for analyzing survival data based on gene expression.
  • Oncomine: A cancer microarray database and integrated data-mining platform.

No new benchmarks or datasets were introduced by the authors.

Key Insights and Ideas

  • SEMA3C as a KRAS G12D-Associated Oncogene: The study strongly links high SEMA3C expression to pancreatic cancers with the KRAS G12D mutation, a common and aggressive subtype. This suggests SEMA3C might be a downstream effector or a co-driver in this specific genetic context.
  • SEMA3C Drives Cancer Progression via Autophagy: The research reveals that SEMA3C actively promotes autophagy, a cellular process that helps cancer cells survive stress and resist treatment. This is a critical insight, as autophagy is known to be upregulated in KRAS-driven cancers.
  • SEMA3C Shapes the Tumor Immune Microenvironment (TME): SEMA3C influences the expression of PD-L1 and M2-like macrophage markers (ARG1/CD163). This suggests SEMA3C actively contributes to an immunosuppressive TME, hindering anti-tumor immune responses.
  • Synergistic Inhibition with KRAS/MEK Pathways: SEMA3C inhibition shows a synergistic effect when combined with KRAS or MEK inhibitors, indicating that targeting SEMA3C could be a valuable strategy to overcome resistance to existing targeted therapies.
  • Therapeutic Potential of SEMA3C Inhibition: The in vivo studies demonstrate that inhibiting SEMA3C significantly retards tumor growth, supporting its role as a viable therapeutic target.

Key Results

  • High SEMA3C expression is associated with decreased survival in pancreatic cancer patients based on TCGA data.
  • SEMA3C knockdown or inhibition leads to growth inhibition, cell cycle arrest, and colony formation impairment in pancreatic cancer cells.
  • SEMA3C overexpression induces autophagy, while its depletion compromises autophagy.
  • SEMA3C inhibition sensitizes pancreatic cancer cells to KRAS or MEK1/2 inhibition.
  • SEMA3C modifies PD-L1 expression in tumor and immune cells and correlates with M2-like macrophage markers.
  • Inhibition of SEMA3C significantly decreased tumor formation in xenograft models.
  • SEMA3C expression is significantly higher in pancreatic cancer cell lines and patients with KRAS G12D mutations.

Limitations and Future Work

  • Limited scope of KRAS mutations studied: While the paper focuses on KRAS G12D, other KRAS mutations might have different dependencies on SEMA3C.
  • Mechanism of SEMA3C-autophagy interaction: While a correlation is shown, the precise molecular mechanisms by which SEMA3C regulates autophagy require further elucidation.
  • Detailed immune cell interactions: The study suggests SEMA3C impacts the TME, but further in-depth investigation into the specific immune cell populations and their interactions mediated by SEMA3C is warranted.
  • Clinical translation: While promising, further preclinical and clinical studies are needed to validate SEMA3C as a therapeutic target in human patients.

The authors suggest that SEMA3C can be used as a novel target or marker with therapeutic or diagnostic potential, particularly in pancreatic cancers harboring the specific KRAS G12D mutation. Future work could focus on developing more specific SEMA3C inhibitors and exploring combination therapies.

Summary updated

Abstract

To date, driver genes for pancreatic cancer treatment are difficult to pursue therapeutically. Targeting mutated KRAS, the most renowned driver gene in pancreatic cancer, is an active area of study. We discovered a gene named SEMA3C was highly expressed in pancreatic cancer cell lines and patients with a G12D mutation in KRAS. High expression of SEMA3C in patients was significantly associated with the decreased survival of pancreatic cancer patients based on the TCGA database. In pancreatic cancer cells, SEMA3C knockdown or inhibition exhibited growth/colony inhibition and cell cycle arrest. In addition, SEMA3C inhibition sensitized KRAS or MEK1/2 inhibition in pancreatic cancer cells. Overexpression of SEMA3C resulted in the induction of autophagy, whereas depletion of SEMA3C compromised induction of autophagy. SEMA3C modified the PD-L1 expression in tumor and immune cells and is correlated with the M2-like macrophage marker ARG1/CD163 expression, which could reshape the tumor microenvironment. Inhibition of SEMA3C decreased tumor formation in the xenograft model <i>in vivo</i>. Taken together, our data suggest that SEMA3C plays a substantial role in promoting cancer cell survival by regulating the autophagy process and impacting the tumor environment immune response. SEMA3C can be used as a novel target or marker with therapeutic or diagnostic potential in pancreatic cancer especially in tumors harboring the specific KRAS G12D mutation.
BibTeX
@inproceedings{zhang2022sema,
  author = {Dalin Zhang and Aaron Lindstrom and Edward Kim and Chang‐Il Hwang and Madison Lee Hall and Tzu‐yin Lin and Yuanpei Li},
  title = {{SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.890154},
}
Figure